CD33 and acute myeloid leukemia: We further demonstrate that CAR T cells that target integrin β2 are efficacious in AML models and, importantly, do not show any evidence of toxicity in normal hematopoietic cells in a humanized immune system (HIS) mouse model, unlike anti-CD33 CAR T cells.